Essential thrombocythemia (ET) is mainly characterized by the abnormal proliferation of a malignant megakaryocytic clone and by persistent thrombocytosis. Recently, a JAK2 mutation (JAK2V617F) has been reported in ET and other myeloproliferative neoplasms.
Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia / Catani, L; Zini, Roberta; Sollazzo, D; Ottaviani, E; Vannucchi, Am; Ferrari, Sergio; Baccarani, M; Vianelli, N; Lemoli, Rm; Manfredini, Rossella. - In: LEUKEMIA. - ISSN 0887-6924. - STAMPA. - 23(5):(2009), pp. 997-1000. [10.1038/leu.2008.357]
Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia.
ZINI, Roberta;FERRARI, Sergio;MANFREDINI, Rossella
2009
Abstract
Essential thrombocythemia (ET) is mainly characterized by the abnormal proliferation of a malignant megakaryocytic clone and by persistent thrombocytosis. Recently, a JAK2 mutation (JAK2V617F) has been reported in ET and other myeloproliferative neoplasms.
| File | Dimensione | Formato | |
|---|---|---|---|
|
42 Catani_leuk_2009.pdf
Solo gestori archivio
Tipologia:
Versione pubblicata dall'editore
Dimensione
159.87 kB
Formato
Adobe PDF
|
159.87 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
